RxDoctor Payments Data

Enrique Martinez, MD

Hepatology · Atlanta, GANPI 1245292218

Payments from drug & device makers

$512,934in general payments, 2019–2025

Across 781 payments — averaging $656.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$336K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$81K
  • Madrigal Pharmaceuticals$57K
  • Novo Nordisk$23K
  • Intercept Pharmaceuticals, Inc.$14K
  • AbbVie$642
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$35,9387%
  • Speaking & faculty fees$405,66079%
  • Travel & lodging$54,19211%
  • Food & beverage$17,1433%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hepatology providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$175,880
Medicare patients
357
Services billed
2,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide213$305,901
XifaxanRifaximin33$121,219
Ursodiol277$50,366
Entecavir17$8,116
Tenofovir Disoproxil Fumarate40$1,753
Budesonide DrBudesonide27$1,439
Mycophenolate Mofetil21$1,141
Spironolactone29$628
Azathioprine22$467
Furosemide17$143
Prednisone38$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$335,838$305,901213 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$81,024$121,21933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other hepatology in Atlanta

Where these figures come from

Is this you, or does something look wrong? →